Geron First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St · 4d ago

Geron (NASDAQ:GERN) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$39.6m (up by US$39.3m from 1Q 2024).
  • Net loss: US$19.8m (loss narrowed by 64% from 1Q 2024).
  • US$0.03 loss per share (improved from US$0.092 loss in 1Q 2024).
earnings-and-revenue-growth
NasdaqGS:GERN Earnings and Revenue Growth May 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Geron EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 18%. Earnings per share (EPS) exceeded analyst estimates by 22%.

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 7.1% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Geron that you should be aware of before investing here.